No evidence for adjuvant chemotherapy in high-risk disease

被引：1
|
作者：
Albers, Peter [1 ]
机构：
[1] Univ Hosp, Dept Urol, D-40225 Dusseldorf, Germany
来源：
NATURE REVIEWS UROLOGY | 2015年 / 12卷 / 11期
关键词：
PROSTATE-CANCER; ANDROGEN SUPPRESSION; TRIAL; RADIOTHERAPY; RADIATION; THERAPY; EORTC;
D O I：
10.1038/nrurol.2015.219
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The RTOG trial investigated the survival benefit of chemotherapy combined with androgen deprivation therapy (ADT) in patients with high-risk nonmetastatic prostate cancer after radiotherapy. However, the 10-year overall survival data showed no difference between treatments; thus, chemotherapy is unlikely to improve the overall survival in patients with nonmetastatic prostate cancer.
引用
收藏
页码：602 / 603
页数：2
相关论文
共 50 条
  • [1] No evidence for adjuvant chemotherapy in high-risk disease
    Peter Albers
    Nature Reviews Urology, 2015, 12 : 602 - 603
  • [2] Adjuvant chemotherapy for high-risk endometrial cancer
    Pustilnik, T
    Burke, TW
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (01) : 23 - 28
  • [3] Adjuvant chemotherapy in high-risk liposarcomas.
    Loehmer, Philipp
    Gronchi, Alessandro
    Brodowicz, Thomas
    Stoeckle, Eberhard
    Callegaro, Dario
    Coindre, Jean -Michel
    Podleska, Lars
    Lamm, Wolfgang
    Fiore, Marco
    Cousin, Sophie
    Treckmann, Juergen
    Schur, Sophie
    Radaelli, Stefano
    Toulmonde, Maud
    Reis, Anna-Carinna
    Colombo, Chiara
    Pottgen, Christoph
    Eisele, Lewin
    Italiano, Antoine
    Bauer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] The rationale for adjuvant chemotherapy for high-risk prostate cancer
    Kent, EC
    Hussain, MHA
    CURRENT OPINION IN UROLOGY, 2003, 13 (02) : 123 - 131
  • [5] Adjuvant chemotherapy for high-risk operable breast cancer
    Buzdar, Aman U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1642 - 1644
  • [6] From adjuvant to neoadjuvant chemotherapy for high-risk breast
    Bonadonna, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 43 - 43
  • [7] Adjuvant Chemotherapy for High-risk Patients With Urothelial Carcinoma
    Morales Barrera, R.
    Suarez, C.
    Nunez, I.
    Valverde, C.
    Serrano, C.
    Castillo Fernandez, O.
    Garcia-Corbacho, J.
    Raventos, C.
    Maldonados, X.
    Carles, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S513 - S513
  • [8] ADJUVANT CHEMOTHERAPY IN HIGH-RISK MALIGNANT-MELANOMA
    KARAKOUSIS, CP
    EMRICH, LJ
    CANCER DRUG DELIVERY, 1986, 3 (01): : 86 - 86
  • [9] ADJUVANT CHEMOTHERAPY IN HIGH-RISK MALIGNANT-MELANOMA
    KARAKOUSIS, CP
    EMRICH, LJ
    JOURNAL OF SURGICAL ONCOLOGY, 1987, 36 (01) : 64 - 67
  • [10] Adoption of adjuvant chemotherapy in high-risk salivary gland malignancies
    Gordon, Alex J.
    Chow, Michael S.
    Patel, Aneek
    Hu, Kenneth S.
    Li, Zujun
    Jacobson, Adam S.
    Vaezi, Alec E.
    Tam, Moses M.
    Givi, Babak
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (01): : 167 - 177
12345